Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNA, U2 small nuclear 1 (RNU2-1), commonly referred to as U2 or U2 snRNA, encodes a highly conserved small nuclear RNA that is an essential component of the major spliceosome in eukaryotic organisms[4][1]. U2 snRNA, assembled into U2 small nuclear ribonucleoprotein (snRNP), is responsible for recognizing the branch point sequence in introns and participates in the catalysis of pre-mRNA splicing by forming base pairs with U6 snRNA and interacting with protein complexes SF3a and SF3b[4][7][3]. This process is fundamental to the maturation of messenger RNA and the regulation of gene expression. U2 snRNAs exhibit extensive post-transcriptional modifications, including pseudouridylation and 2’-O-methylation[4]. Its loci are associated with specialized nuclear domains (coiled bodies), indicating a spatial organization of snRNA transcription and processing[5]. Disease relevance is primarily through recurrent mutations that have been observed in certain tumor types, but it is not considered a classical therapeutic target such as a receptor, enzyme, or transporter[2][1][4].
Not applicable; U2 snRNA is not directly drug-targeted.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U2 small nuclear 1 (RNU2-1).